Maksim Labkouski
INVO Bioscience (NASDAQ:INVO) and NAYA Biosciences said they expect their planned merger to close in Q1 and announced several additions to their future combined board.
NAYA said it has appointed Laurent Audoly, Lyn Falconio, Prakash Raman, Mark Rothera and Patrick Tricoli to its board. The new members will continue in their roles post-merger to serve on the combined company’s board.
Audoly is an executive partner at Apollo Health Ventures and co-founder and former CEO of Kymera Therapeutics (KYMR), while Raman is CEO of Ribon Therapeutics and a former global head of business development at Novartis Institute of Biomedical Research and Novartis Oncology.
Falconio is executive engagement lead at Publicis, while Tricoli is CEO of Nanobiotix (NBTX). Rothera is CEO of Viracta Therapeutics and also served as CEO of Silence Therapeutics and Orchard Therapeutics.
INVO said it has filed its S-4 registration and preliminary joint proxy statements in preparation for the merger.